Beneficial effects of renal sympathetic denervation on cardiovascular inflammation and remodeling in essential hypertension

详细信息    查看全文

• 作者：Oliver D?rr ; Christoph Liebetrau ; Helge M?llmann…
• 关键词：Hypertension ; Renal denervation ; Remodeling ; Inflammation
• 刊名：Clinical Research in Cardiology
• 出版年：2015
• 出版时间：February 2015
• 年：2015
• 卷：104
• 期：2
• 页码：175-184
• 全文大小：485 KB
• 参考文献：1. Task force for the management of arterial hypertension of the European Society of Cardiology (2007) Guidelines for the management of arterial hypertension. Eur Heart J 28:1462-536
  2. Mendall MA, Patel P, Asante M, Ballam L, Morris J, Strachan DP, Camm AJ, Northfield TC (1997) Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart 78:273-77 CrossRef
  3. Furumoto T, Saito N, Dong J, Mikami T, Fujii S, Kitabatake A (2002) Association of cardiovascular risk factors and endothelial dysfunction in Japanese hypertensive patients: implications for early athero- sclerosis. Hypertens Res 25:475-80 CrossRef
  4. B?hm M, Voors A, Ketelslegers JM, Schirmer SH, Turgonyi E, Bramlage P, Zannad F (2011) Biomarkers: optimizing treatment guidance in heart failure. Clin Res Cardiol 100:973-81 CrossRef
  5. Breda L, Di Marzio D, Giannini C, Gaspari S, Nozzi M, Scarinci A, Chiarelli F, Mohn A (2013) (2013Relationship between inflammatory markers, oxidant–antioxidant status and intima-media thickness in prepubertal children with juvenile idiopathic arthritis. Clin Res Cardiol 102:63-1 CrossRef
  6. Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, Ricart W (2001) Circulating interleukin-6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 86:1154-159 CrossRef
  7. Lok D, Lok S, de la Porte PBA, Badings E, Lipsic E, van Wijngaarden J, de Boer R, Dvan Veldhuisen DJ, van der Meer P (2013) Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol 102:103-11 CrossRef
  8. Fassbach M, Schwartzkopff B (2005) Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction. Z Kardiol 94:328-35 CrossRef
  9. Intengan HD, Schiffrin EL (2000) Structure and mechanical properties of resistance arteries in hypertension. Role of adhesion molecules and extracellular matrix determinants. Hypertension 36:312-18 CrossRef
  10. Li-Saw-Hee FL, Edmunds E, Blann AD, Beevers DG, Lip GY (2000) Matrix metalloproteinase-9 and tissue inhibitor metallopro- teinase-1 levels in essential hypertension. Relation- ship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 75:43-7 CrossRef
  11. Laurent S (1995) Arterial wall hypertrophy and stiffness in essential hypertensive patients. Hypertension 26:355-62 CrossRef
  12. Lindsay M, Maxwell P, Dunn FG (2002) TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 40:136-41 CrossRef
  13. Madhavan S, Ooi WL, Cohen H, Alderman MH (1994) Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 23:395-01 CrossRef
  14. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM, American Heart Association Professional Education Committee (2008) Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 117:510-26 CrossRef
  15. Lloyd-Jones D, Adams R, Carnethon M (2009) Heart disease and stro
• 刊物主题：Cardiology;
• 出版者：Springer Berlin Heidelberg
• ISSN：1861-0692

文摘

Background Renal sympathetic denervation (RSD) represents a potential treatment option for certain patients with resistant arterial hypertension (HT). HT is associated with chronic vascular inflammation and remodeling, contributing to progressive vascular damage, and atherosclerosis. The present study aimed to evaluate the influence of RSD on cardiovascular inflammation and remodeling by determining serum levels of interleukin-6 (IL-6), high-sensitive C-reactive protein (hsCRP), matrix metalloproteinases (MMP), and tissue inhibitor of metalloproteinases (TIMP). Methods A total of 60 consecutive patients (age 67.9?±?9.6?years) undergoing RSD were included. A therapeutic response was defined as an office systolic blood pressure (SBP) reduction of >10?mmHg 6?months after RSD. Venous serum samples for measurement of hsCRP, IL-6, MMP-2, MMP-9, and TIMP-1 were collected prior to and 6?months after RSD. Results A significant reduction in office SBP of 26.4?mmHg [SBPbaseline 169.3?mmHg (SD 11.3), p?hsCRP (p?p?MMP-9 (p?=?0.024) and MMP-2 (p? Conclusion In addition to the effective blood pressure reduction in response to RSD, this study demonstrates a positive effect of RSD on biomarkers reflecting vascular inflammation and remodeling. These results suggest a possible prognostic benefit of RSD in high-risk patients for endothelial dysfunction and cardiovascular remodeling as well as end-organ damage.